In type 2 diabetes mellitus which is characterized by increased non-enzymatic protein glycosylation because of chronic hyperglycemia, GLP-1R agonists might also improve defective glucose transport and glycometabolic control by stimulating AMPK phosphorylation. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.